Table 3. Synergistic combinations of CHM compounds or CHMs with chemotherapeutic drugs in clinical.

CHM Compounds/CHMs	Chemotherapeutic Drugs	Designs	Case Numbers	Cancers	Clinical Outcomes	Refs.
Arsenic trioxide	ascorbic acid+melphalan	prospective, multicentre, single-arm	65	multiple myeloma	↑ therapeutic effect and tolerance	[104]
	all-trans retinoic acid	randomized, controlled	61	acute promyelocytic leukemia	↑ quality of complete remission, the status of the disease-free survival	[105]
	dexamethasone+ascorbic acid	a phase 2 trial.	20	multiple myeloma	↑tolerance;↓ adverse events	[106]
Mistletoe extract	cyclophosphamide + adriamycin +cisplatin /cyclophosphamide +adriamycin +5-fluorouracil	Prospective, Randomized, Controlled	68	breast cancer	↑quality of life;↓reduce the side-effects	[107]
	cyclophosphamide +cisplatin/ifosfamide +carboplatin	A Prospective Randomized Controlled Clinical Trial	71	ovarian cancer	↑ quality of life;↓reduce the side-effects	[107]
	vinorelbine +cisplatin /mitomycine+vindesine +cisplatin	A Prospective Randomized Controlled Clinical Trial	94	non-small cell lung cancer	↑ quality of life;↓reduce the side-effects	[107]
	cyclophosphamide+methotrexate+fluorouracil	randomised, placebo-controlled, double-blind, multicentre	272	breast cancer	↑ quality of life	[108]
	cisplatin+5-fluorouracil/5-fluorouracil	randomized, controlled	20	ear, nose and throat carcinoma	↑ immunological reactions, microcirculation	[109]
Turmeric powder	imatinib	randomized, controlled	50	chronic myeloid leukemia	↑ therapuetic effect	[88]
Astragalus polysaccharide injection	vinorelbine and cisplatin	randomized, controlled	136	non-small cell lung cancer	↑ therapeutic effect, quality of life ; ↓reduce the side-effects	[110]
Cimicifuga racemosa	tamoxifen	prospective	50	breast cancer	↓ psychovegetative symptoms	[111]
Scutellaria baicalensis	irinotecan	randomized, controlled	44	non-small cell lung cancer	↓ gastrointestinal toxicity	[112]

↑: Up-regulation

↓: Down-regulation